Shintaro Fukushima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shintaro Fukushima has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Renhe Jiang
The University of Tokyo, Tokyo, Japan
3 shared publications - Chuang Yang
The University of Tokyo
2 shared publications - Hongjun Wang
The University of Tokyo, Tokyo, Japan
2 shared publications - Jiawei Yong
Toyota Motor Corporation, Tokyo, Japan
2 shared publications Takeyuki Sasai
2 shared publications- Tomoki Nishi
TOYOTA CENTRAL R&D LABS., INC., Aichi, Japan
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Elsevier in Transportation Research Part C: Emerging Technologies
- Vol. 192
TrajGPT-R: Generating urban mobility trajectory with reinforcement Learning-Enhanced generative Pre-trained transformer
- 15 July 2026
- Published by Elsevier in Transportation Research Part C: Emerging Technologies
- Vol. 192
Open AccessTrajGPT-R: Generating urban mobility trajectory with reinforcement Learning-Enhanced generative Pre-trained transformer
- Open Access
- 20 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1424-1434
Towards Resilient Transportation: A Conditional Transformer for Accident-Informed Traffic Forecasting
- 20 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1424-1434
Open AccessTowards Resilient Transportation: A Conditional Transformer for Accident-Informed Traffic Forecasting
- Open Access
- 21 November 2025
- Published by Elsevier in Transportation Research Part D: Transport and Environment
- Vol. 150
Charging behavior differences between BEVs and PHEVs: Evidence from vehicle log data
- 21 November 2025
- Published by Elsevier in Transportation Research Part D: Transport and Environment
- Vol. 150
Open AccessCharging behavior differences between BEVs and PHEVs: Evidence from vehicle log data
- Open Access
- 22 September 2025
- Published by Association for Computing Machinery (ACM)
- p. 660-665
Popularity‑Bias Vulnerability: Semi‑Supervised Label Inference Attack on Federated Recommender Systems
- 22 September 2025
- Published by Association for Computing Machinery (ACM)
- p. 660-665
Open AccessPopularity‑Bias Vulnerability: Semi‑Supervised Label Inference Attack on Federated Recommender Systems
- Open Access
- 15 July 2025
- Published by Elsevier in Transportation Research Part D: Transport and Environment
- Vol. 146
How to improve PHEV electric mileage ratios? Factor decomposition with Explainable AI
- 15 July 2025
- Published by Elsevier in Transportation Research Part D: Transport and Environment
- Vol. 146
Open AccessHow to improve PHEV electric mileage ratios? Factor decomposition with Explainable AI
- Open Access
- 13 November 2023
- Published by Association for Computing Machinery (ACM)
- p. 1-10
Revisiting Mobility Modeling with Graph: A Graph Transformer Model for Next Point-of-Interest Recommendation
- 13 November 2023
- Published by Association for Computing Machinery (ACM)
- p. 1-10
Open AccessRevisiting Mobility Modeling with Graph: A Graph Transformer Model for Next Point-of-Interest Recommendation
- 17 March 2013
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 31 (1) , 11-16
Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation
Actinin-4 is an isoform of nonmuscular α-actinin and actin-bundling protein that plays an important role in cancer invasion and metastasis by enhancing cellular motility. Recent studies have revealed an association between several clinicopathological profiles and actinin-4 overexpression in human cancers. In this study, we investigated the immunohistochemical actinin-4 expression in 39 infiltrating gliomas. The specimens included three diffuse astrocytomas, three oligodendrogliomas, one oligoastrocytoma, two anaplastic astrocytomas, four anaplastic oligodendrogliomas, three anaplastic oligoastrocytomas, 17 glioblastomas, four gliosarcomas, and two glioblastomas with oligodendroglial component. All seven World Health Organization (WHO) grade II tumors were negative for actinin-4, whereas 20 of 22 tumors with strong actinin-4 expression were WHO grade IV. Actinin-4 expression was significantly associated with histological grade (P < 0.0001) and proliferative activity measured by Ki-67 staining (P = 0.0045). Notably, actinin-4 expression was more pronounced in high-grade astrocytic tumors than oligodendroglial tumors (P < 0.0001). Additionally, pseudopalisading cells in glioblastoma exhibited stronger actinin-4 expression than the rest, likely reflecting enhanced cellular motility in pseudopalisades. This study is the first to demonstrate significant correlation between actinin-4 expression and tumor grade using clinical glioma samples. Although diagnostic utility of this marker awaits future exploration, actinin-4 may help distinguish between astrocytic and oligodendroglial lines of differentiation.
- 17 March 2013
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 31 (1) , 11-16
Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation
Actinin-4 is an isoform of nonmuscular α-actinin and actin-bundling protein that plays an important role in cancer invasion and metastasis by enhancing cellular motility. Recent studies have revealed an association between several clinicopathological profiles and actinin-4 overexpression in human cancers. In this study, we investigated the immunohistochemical actinin-4 expression in 39 infiltrating gliomas. The specimens included three diffuse astrocytomas, three oligodendrogliomas, one oligoastrocytoma, two anaplastic astrocytomas, four anaplastic oligodendrogliomas, three anaplastic oligoastrocytomas, 17 glioblastomas, four gliosarcomas, and two glioblastomas with oligodendroglial component. All seven World Health Organization (WHO) grade II tumors were negative for actinin-4, whereas 20 of 22 tumors with strong actinin-4 expression were WHO grade IV. Actinin-4 expression was significantly associated with histological grade (P < 0.0001) and proliferative activity measured by Ki-67 staining (P = 0.0045). Notably, actinin-4 expression was more pronounced in high-grade astrocytic tumors than oligodendroglial tumors (P < 0.0001). Additionally, pseudopalisading cells in glioblastoma exhibited stronger actinin-4 expression than the rest, likely reflecting enhanced cellular motility in pseudopalisades. This study is the first to demonstrate significant correlation between actinin-4 expression and tumor grade using clinical glioma samples. Although diagnostic utility of this marker awaits future exploration, actinin-4 may help distinguish between astrocytic and oligodendroglial lines of differentiation.